GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (TSE:2160) » Definitions » Debt-to-Revenue

GNI Group (TSE:2160) Debt-to-Revenue : 0.26 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is GNI Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

GNI Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円4,627 Mil. GNI Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円1,607 Mil. GNI Group's annualized Revenue for the quarter that ended in Mar. 2024 was 円23,794 Mil. GNI Group's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.26.


GNI Group Debt-to-Revenue Historical Data

The historical data trend for GNI Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Debt-to-Revenue Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.18 0.09 0.03 0.14

GNI Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.06 0.17 0.26

Competitive Comparison of GNI Group's Debt-to-Revenue

For the Biotechnology subindustry, GNI Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where GNI Group's Debt-to-Revenue falls into.



GNI Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

GNI Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1949.158 + 1750.276) / 26010.571
=0.14

GNI Group's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4626.9 + 1606.923) / 23794.276
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


GNI Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of GNI Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (TSE:2160) Business Description

Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (TSE:2160) Headlines

No Headlines